Biogen Says Government Is Probing Its Drug Prices, Rebates, Buyer Assist Efforts

(July 22, 2016, 10:38 AM EDT) -- CAMBRIDGE, Mass. — Biotechnology company Biogen Inc. said July 21 that it received civil investigative demands on July 1 from the federal government for documents and information relating to the company’s treatment of “certain service agreements with wholesalers when calculating and reporting Average Manufacturing Prices in connection with the Medicaid Drug Rebate Program.”...

Related Sections